The HR (95% CI) for symptoms by region and specific symptoms in the ARIALL group (n=78) (univariate model)
| Symptom | HR (95% CI)* (ratio of the hazard of RTP for an individual with the symptom compared with the hazard of RTP for an individual without the symptom RTP) | P value † |
| Nose and throat | ||
| Sore/scratchy throat | 1.01 (0.59 to 1.71) | 0.986 |
| Hoarseness | 0.68 (0.34 to 1.34) | 0.262 |
| Blocked/plugged nose | 1.23 (0.70 to 2.16) | 0.476 |
| Runny nose | 1.29 (0.76 to 2.20) | 0.344 |
| Sinus pressure | 0.96 (0.57 to 1.65) | 0.907 |
| Sneezing | 1.06 (0.61 to 1.85) | 0.843 |
| Altered/loss sense of smell | 0.49 (0.28 to 0.84) | 0.009 |
| Altered/loss sense of taste | 0.58 (0.34 to 1.00) | 0.050 |
| Chest and neck | ||
| Dry cough | 0.64 (0.37 to 1.10) | 0.104 |
| Wet cough | 1.01 (0.54 to 1.89) | 0.978 |
| Difficulty in breathing | 0.52 (0.30 to 0.91) | 0.022 |
| Fast breathing or shortness of breath | 0.65 (0.37 to 1.13) | 0.121 |
| Chest pain/pressure | 0.52 (0.29 to 0.95) | 0.033 |
| Chest tightness | 0.96 (0.54 to 1.68) | 0.875 |
| Headache | 0.44 (0.25 to 0.79) | 0.006 |
| Red/watery/scratchy eyes | 0.90 (0.49 to 1.65) | 0.729 |
| Whole body | ||
| Fever | 0.36 (0.18 to 0.73) | 0.004 |
| Chills | 0.35 (0.17 to 0.72) | 0.004 |
| Excessive fatigue | 0.25 (0.13 to 0.47) | <0.0001 |
| General muscle aches and pains | 0.83 (0.49 to 1.41) | 0.496 |
| Skin rash† | – | – |
| Abdominal pain† | – | – |
| Nausea | 0.51 (0.25 to 1.04) | 0.063 |
| Vomiting† | – | – |
| Diarrhoea† | – | – |
| Loss of appetite | 0.53 (0.31 to 0.91) | 0.022 |
*An HR <1 indicates a lower chance of RTP in the 40-day period after the onset of symptoms for an individual with the symptom compared with an individual without the symptom, that is, prolonged RTP.
†Symptoms where the numbers were too small (<15 events) to analyse between groups or produce CIs.
‡Type 3 test.
ARI, acute respiratory illness; ARICOV, acute respiratory illness COVID-19 subgroup; ARIOTH, acute respiratory illness Other subgroup; RTP, return to play.